These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1657 related items for PubMed ID: 16259525

  • 1. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A, Husser D, Cannom DS.
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [Abstract] [Full Text] [Related]

  • 2. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV, Wolbrette DL, Khan M, Bhatta L, Hynes J, Samii S, Luck J.
    Am J Cardiol; 2003 Mar 20; 91(6A):15D-26D. PubMed ID: 12670638
    [Abstract] [Full Text] [Related]

  • 3. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS, Zehender M.
    Ther Umsch; 2000 May 20; 57(5):324-32. PubMed ID: 10859993
    [Abstract] [Full Text] [Related]

  • 4. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA, Banchs JE, Depalma S, Young SK, Penny-Peterson ED, Samii SM, Wolbrette DL, Naccarelli GV, Gonzalez MD.
    J Cardiovasc Electrophysiol; 2012 Mar 20; 23(3):296-301. PubMed ID: 21955243
    [Abstract] [Full Text] [Related]

  • 5. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
    Hohnloser SH, Dorian P, Roberts R, Gent M, Israel CW, Fain E, Champagne J, Connolly SJ.
    Circulation; 2006 Jul 11; 114(2):104-9. PubMed ID: 16818810
    [Abstract] [Full Text] [Related]

  • 6. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
    Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K, Champagne J, Talajic M, Coutu B, Gronefeld GC, Hohnloser SH, Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators.
    JAMA; 2006 Jan 11; 295(2):165-71. PubMed ID: 16403928
    [Abstract] [Full Text] [Related]

  • 7. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.
    Ho AT, Pai SM, Timothy P, Pai RG.
    Pacing Clin Electrophysiol; 2005 Jul 11; 28(7):647-53. PubMed ID: 16008799
    [Abstract] [Full Text] [Related]

  • 8. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
    Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C.
    Cochrane Database Syst Rev; 2019 Sep 04; 9(9):CD005049. PubMed ID: 31483500
    [Abstract] [Full Text] [Related]

  • 9. Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators.
    Lee CH, Nam GB, Park HG, Kim HY, Park KM, Kim J, Choi KJ, Kim YH.
    Circ J; 2008 Jan 04; 72(1):102-5. PubMed ID: 18159108
    [Abstract] [Full Text] [Related]

  • 10. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review.
    Hilleman DE, Bauman AL.
    Pharmacotherapy; 2001 May 04; 21(5):556-75. PubMed ID: 11349745
    [Abstract] [Full Text] [Related]

  • 11. [Current role of amiodarone in antiarrhythmic therapy].
    Sohns C, Zabel M.
    Herzschrittmacherther Elektrophysiol; 2010 Dec 04; 21(4):239-43. PubMed ID: 21104260
    [Abstract] [Full Text] [Related]

  • 12. Role of antiarrhythmic drugs: frequent implantable cardioverter-defibrillator shocks, risk of proarrhythmia, and new drug therapy.
    Droogan C, Patel C, Yan GX, Kowey PR.
    Heart Fail Clin; 2011 Apr 04; 7(2):195-205, viii. PubMed ID: 21439498
    [Abstract] [Full Text] [Related]

  • 13. Significance and control of cardiac arrhythmias in patients with congestive cardiac failure.
    Singh BN.
    Heart Fail Rev; 2002 Jul 04; 7(3):285-300. PubMed ID: 12215733
    [Abstract] [Full Text] [Related]

  • 14. New advances in class III antiarrhythmic drug therapy.
    Sager PT.
    Curr Opin Cardiol; 2000 Jan 04; 15(1):41-53. PubMed ID: 10666660
    [Abstract] [Full Text] [Related]

  • 15. Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest.
    Haverkamp W, Eckardt L, Borggrefe M, Breithardt G.
    Am J Cardiol; 1997 Oct 23; 80(8A):67G-73G. PubMed ID: 9354413
    [Abstract] [Full Text] [Related]

  • 16. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.
    Dorian P, Borggrefe M, Al-Khalidi HR, Hohnloser SH, Brum JM, Tatla DS, Brachmann J, Myerburg RJ, Cannom DS, van der Laan M, Holroyde MJ, Singer I, Pratt CM, SHock Inhibition Evaluation with azimiLiDe (SHIELD) Investigators.
    Circulation; 2004 Dec 14; 110(24):3646-54. PubMed ID: 15533855
    [Abstract] [Full Text] [Related]

  • 17. Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.
    AbdelWahab A, Sapp J.
    Curr Cardiol Rep; 2017 Sep 13; 19(11):105. PubMed ID: 28900864
    [Abstract] [Full Text] [Related]

  • 18. Amiodarone: clinical trials.
    Naccarelli GV, Wolbrette DL, Patel HM, Luck JC.
    Curr Opin Cardiol; 2000 Jan 13; 15(1):64-72. PubMed ID: 10666663
    [Abstract] [Full Text] [Related]

  • 19. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B, Pedersen O, Torp-Pedersen C, Sahebzadah N, Køber L.
    Drug Saf; 2002 Jan 13; 25(12):847-65. PubMed ID: 12241126
    [Abstract] [Full Text] [Related]

  • 20. Implantable cardioverter defibrillator therapy and the need for concomitant antiarrhythmic drugs.
    Singh S, Murawski MM.
    J Cardiovasc Pharmacol Ther; 2007 Sep 13; 12(3):175-80. PubMed ID: 17875944
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 83.